Stockscreener 앱 받기
34.75
2.10%
-0.778
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap DownHere's What Happened - MarketBeat
Market Outlook: Does Oruka Therapeutics Inc stock have upside surprise potential2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Fed Meeting: Will Oruka Therapeutics Inc outperform tech stocksJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn
RSI Check: Can GLPG outperform under higher oil pricesJuly 2025 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighWhat's Next? - MarketBeat
Gains Report: Will Oruka Therapeutics Inc benefit from AI trendsGold Moves & Reliable Momentum Entry Alerts - baoquankhu1.vn
Aug Opening: Will ARTV outperform the market in YEAR2025 Major Catalysts & Low Drawdown Trading Techniques - baoquankhu1.vn
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Update - MarketBeat
Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.65 USD By Investing.com - Investing.com Nigeria
Oruka Therapeutics (ORKA) Is Up 23.1% After Extended-Dosing IL-17 Data for ORKA-002What's Changed - Sahm
Oruka Therapeutics stock hits 52-week high at 32.65 USD - Investing.com India
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighHere's Why - MarketBeat
Pullback Watch: What is Oruka Therapeutics Incs book value per shareJuly 2025 Review & Fast Entry Momentum Alerts - baoquankhu1.vn
Oruka Therapeutics (ORKA) Price Target Increased by 12.54% to 56.44 - Nasdaq
Clear Street raises Oruka Therapeutics stock price target on promising drug data - Investing.com Canada
Oruka reports positive interim data for ORKA-002 in Phase 1 trial - Investing.com Nigeria
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001 - Dermatology Times
BTIG Research Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price - MarketBeat
Oruka reports positive interim data for ORKA-002 in Phase 1 trial By Investing.com - Investing.com South Africa
Oruka Therapeutics, Inc. Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of Everlong-B Trial of ORKA-001 - marketscreener.com
Earnings Risk: Is OPFI affected by consumer sentimentJuly 2025 Highlights & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from Analysts at UBS Group - Defense World
Aug Outlook: Why Oruka Therapeutics Inc. stock is favored by top institutions2025 Retail Activity & Real-Time Volume Spike Alerts - Улправда
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Unpacking a 97.60% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Oruka Therapeutics (NASDAQ:ORKA) Rating Increased to Strong-Buy at UBS Group - MarketBeat
ORKA-001 psoriasis trial: Fresh phase 2 update and what it means for investors - MSN
Does UBS’s New Coverage Reframe Oruka Therapeutics (ORKA) as a Peptide Platform, Not Just a Biotech? - Sahm
How buybacks impact Oruka Therapeutics Inc. stock valueJuly 2025 Macro Moves & Risk Controlled Swing Alerts - ulpravda.ru
Can Oruka Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - Улправда
Will Oruka Therapeutics Inc. (HQ1) stock top growth indexes2025 Market WrapUp & Precise Swing Trade Entry Alerts - ulpravda.ru
Why Oruka Therapeutics Inc. stock is a must watch in 2025Earnings Beat & AI Powered Market Entry Strategies - Улправда
Is Oruka Therapeutics Inc. (HQ1) stock undervalued historicallyJuly 2025 Technicals & Reliable Price Breakout Alerts - Улправда
What sentiment indicators say about Oruka Therapeutics Inc. stockJuly 2025 Institutional & Technical Buy Zone Confirmations - Улправда
Is Oruka Therapeutics Inc. stock a dividend growth opportunity - Улправда
Dental EconomicsOruka Therapeutics, Inc.Common Stock (Nasdaq:ORKA) Detailed Stock Data - FinancialContent
Oruka Therapeutics stock initiated with Buy rating at UBS on cancer drug potential - Investing.com UK
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears - Seeking Alpha
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 8.3%What's Next? - MarketBeat
Insider Sell Alert: Laura Sandler Sells 13,000 Shares of Oruka T - GuruFocus
Oruka Therapeutics COO Sandler sells $370,795 in shares By Investing.com - Investing.com Canada
Oruka Therapeutics COO Sandler sells $370,795 in shares - Investing.com UK
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Up 4.3% – Time to Buy? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 4.3%Should You Buy? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.3%Time to Sell? - MarketBeat
Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) and Oruka Therapeutics (NASDAQ:ORKA) Financial Survey - Defense World
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin - Sahm
Oruka Therapeutics stock hits 52-week high at 32.31 USD By Investing.com - Investing.com Australia
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.31 USD - Investing.com India
4.38%
1.75%
자본화:
|
볼륨(24시간):